DD Stock Forecast & Price Target

DuPont de Nemours is well positioned by its shift toward higher-quality, higher-multiple businesses, with Healthcare and Water Technologies delivering mid-single-digit organic sales growth and expected to remain the main profit engines. The company is generating solid free cash flow, with >100% cash conversion in Q2, a further $250M share-repurchase program in 2026, and roughly $1B available for bolt-on opportunities, supporting both shareholder returns and growth investment. Its balance sheet has improved materially after about $5B of debt repayment, while continued organic improvement, healthy margins near 24.5%, and exposure to aerospace, biopharma, and semiconductor end markets underpin a constructive outlook into 2027.

DuPont de Nemours is viewed cautiously because its recovery depends on a slower-than-expected rebound in China and North America, while continued weakness in electronics and construction could keep demand pressured. Its negative outlook is also tied to synergy and integration challenges, along with the risk that management delays or fails to optimize the spin strategy and the electronics business separation. In the downside scenario, 2026E EBITDA of $2.17 and a 21x multiple imply only $46 of value, underscoring how execution setbacks and weak end markets could weigh on fundamentals.